Trial Profile
An Open Label, Phase 2 Study of Ibrutinib in Combination With Rituximab and Lenalidomide in Previously Untreated Subjects With Follicular Lymphoma and Marginal Zone Lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Nov 2023
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Lenalidomide; Rituximab
- Indications Follicular lymphoma; Marginal zone B-cell lymphoma
- Focus Therapeutic Use
- 20 Nov 2023 Results assessing the efficacy and safety of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma, published in the Cancer.
- 22 Aug 2023 Status changed from active, no longer recruiting to completed.
- 09 Feb 2023 Planned End Date changed from 31 Aug 2022 to 31 Aug 2023.